A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer By Ogkologos - November 21, 2025 385 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Efficacy and Safety of Trastuzumab Deruxtecan in Exploratory Cohorts of Patients... November 23, 2022 ER-Low Positive Breast Cancer Shows Similar Clinical Behaviour and Response to... August 6, 2021 EMA Recommends Granting a Marketing Authorisation for Poherdy April 10, 2026 NCI Part of Federal Effort to Evaluate Antibody Tests for Novel... May 5, 2020 Load more HOT NEWS ESMO Publishes First-Ever Guidance on Validation Requirements for AI-Based Biomarkers in... Spirituality Resources ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer... One in Five of Older Patients with EBC Treated in a...
